Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H46O2 |
| Molecular Weight | 366.6208 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O
InChI
InChIKey=GWHCXVQVJPWHRF-KTKRTIGZSA-N
InChI=1S/C24H46O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26/h9-10H,2-8,11-23H2,1H3,(H,25,26)/b10-9-
Nervonic acid is a long chain unsaturated fatty acid that is enriched in sphingomyelin. It consists of choline, sphingosine, phosphoric acid, and fatty acid. Nervonic acid may enhance the brain functions and prevent demyelination (Chemical Land21). Research shows that there is negative relationship between nervonic acid and obesity-related risk factors. Demyelination in adrenoleukodystrophy (ALD) is associated with an accumulation of very long chain saturated fatty acids stemming from a genetic defect in the peroxisomal beta oxidation system responsible for the chain shortening of these fatty acids. Sphingolipids from post mortem ALD brain have decreased levels of nervonic acid, 24:1(n-9), and increased levels of stearic acid, 18:0. Nervonic acid (C24:1), a component of membrane sphingolipids and phosphatidylethanolamines, may be a useful predictor of chronic kidney disease mortality and diabetes. Nervonic acid oils are being studied for pharmaceutical, nutraceutical and industrial applications. Nervonic acid is a major component of Lunaria oil. There is increasing evidence that dietary supplementation with nervonic acid is healthy for babies and infants during the early stage of brain development. Nervonic acid has been reported to reduce the shaking associated with Parkinson’s disease and the numbness caused by multiple sclerosis. It also has potential for treating schizophrenia and reducing early Alzheimer’s symptoms.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4343 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9367179 |
4.0 µM [Ki] | ||
Target ID: 534848.0 Gene Symbol: POLA1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9367179 |
0.3 µM [Ki] | ||
| 1.2 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Site-directed mutational analysis of structural interactions of low molecule compounds binding to the N-terminal 8 kDa domain of DNA polymerase beta. | 2006-11-10 |
|
| Serum phospholipid fatty acids, adipose tissue, and metabolic markers in obese adolescents. | 2006-11 |
|
| Serum lipid fatty acids and temporal processing acuity in children with oral clefts. | 2006-04 |
|
| Relationships between serum unsaturated fatty acids and coronary risk factors: negative relations between nervonic acid and obesity-related risk factors. | 2005-11 |
|
| Arachidonic acid predominates in the membrane phosphoglycerides of the early and term human placenta. | 2005-11 |
Sample Use Guides
Since Nervonic acid is almost insoluble in water, it often sold in the form of capsules. Generally speaking, two capsules orally every time, and two doses or two times a day, one in the morning, and the other in the evening. The recommended dosage ranges from 200mg to 300mg of pure nervonic acid.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9367179
Nervonic acid (NA) most effectively inhibited calf DNA polymerase a activity; its
minimum inhibitory concentration MIC was 2 uM. NA 10 uM completely suppressed the activities of both polymerases (calf DNA polymerase a and rat DNA polymerase b).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
3247 (Number of products:9)
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
||
|
NCI_THESAURUS |
C68423
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C68395
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | NCIT | ||
|
300000015660
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | |||
|
506-37-6
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | |||
|
44247
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | |||
|
NERVONIC ACID
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | |||
|
DTXSID801009308
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | |||
|
5281120
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY | |||
|
91OQS788BE
Created by
admin on Mon Mar 31 21:27:43 GMT 2025 , Edited by admin on Mon Mar 31 21:27:43 GMT 2025
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD